Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more
Avadel Pharmaceuticals PLC (AVDL) - Net Assets
Latest net assets as of September 2025: $98.22 Million USD
Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has net assets worth $98.22 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($199.45 Million) and total liabilities ($101.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $98.22 Million |
| % of Total Assets | 49.25% |
| Annual Growth Rate | 4.24% |
| 5-Year Change | -54.49% |
| 10-Year Change | 8.82% |
| Growth Volatility | 269.81 |
Avadel Pharmaceuticals PLC - Net Assets Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual net assets of Avadel Pharmaceuticals PLC from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $73.85 Million | -15.83% |
| 2023-12-31 | $87.74 Million | +514.94% |
| 2022-12-31 | $-21.14 Million | -127.02% |
| 2021-12-31 | $78.24 Million | -51.78% |
| 2020-12-31 | $162.27 Million | +655.72% |
| 2019-12-31 | $-29.20 Million | -1150.32% |
| 2018-12-31 | $2.78 Million | -96.71% |
| 2017-12-31 | $84.56 Million | +101.01% |
| 2016-12-31 | $42.07 Million | -38.01% |
| 2015-12-31 | $67.86 Million | +172.60% |
| 2014-12-31 | $24.89 Million | +361.72% |
| 2013-12-31 | $-9.51 Million | -131.18% |
| 2012-12-31 | $30.50 Million | +2.38% |
| 2011-12-31 | $29.79 Million | -17.93% |
| 2010-12-31 | $36.30 Million | -19.08% |
| 2009-12-31 | $44.86 Million | -7.59% |
| 2008-12-31 | $48.55 Million | -11.13% |
| 2007-12-31 | $54.63 Million | -25.20% |
| 2006-12-31 | $73.03 Million | -15.73% |
| 2005-12-31 | $86.65 Million | -25.78% |
| 2004-12-31 | $116.76 Million | +26.83% |
| 2003-12-31 | $92.06 Million | +649.32% |
| 2002-12-31 | $12.29 Million | +63.62% |
| 2001-12-31 | $7.51 Million | -31.00% |
| 2000-12-31 | $10.88 Million | +20.02% |
| 1999-12-31 | $9.07 Million | -49.02% |
| 1998-12-31 | $17.79 Million | +24.37% |
| 1997-12-31 | $14.30 Million | -38.10% |
| 1996-12-31 | $23.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avadel Pharmaceuticals PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 76862800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $965.00K | 1.31% |
| Other Comprehensive Income | $-24.58 Million | -33.28% |
| Other Components | $891.79 Million | 1207.60% |
| Total Equity | $73.85 Million | 100.00% |
Avadel Pharmaceuticals PLC Competitors by Market Cap
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Siriuspoint Ltd
NYSE:SPNT
|
$1.98 Billion |
|
Gold Road Resources Limited
PINK:ELKMF
|
$1.98 Billion |
|
Indian Railway Finance Corporation Limited
NSE:IRFC
|
$1.98 Billion |
|
Harley-Davidson Inc
NYSE:HOG
|
$1.98 Billion |
|
Sime Darby Bhd
KLSE:4197
|
$1.98 Billion |
|
SIGMASTAR TECH LTD
SHE:301536
|
$1.98 Billion |
|
Mobimo Holding AG
LSE:0QQY
|
$1.98 Billion |
|
Pou Chen Corp
TW:9904
|
$1.98 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avadel Pharmaceuticals PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 87,739,000 to 73,848,000, a change of -13,891,000 (-15.8%).
- Net loss of 48,832,000 reduced equity.
- New share issuances of 9,250,000 increased equity.
- Other comprehensive income decreased equity by 1,413,000.
- Other factors increased equity by 27,104,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-48.83 Million | -66.13% |
| Share Issuances | $9.25 Million | +12.53% |
| Other Comprehensive Income | $-1.41 Million | -1.91% |
| Other Changes | $27.10 Million | +36.7% |
| Total Change | $- | -15.83% |
Book Value vs Market Value Analysis
This analysis compares Avadel Pharmaceuticals PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 8.08x to 27.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $2.68 | $21.64 | x |
| 1997-12-31 | $1.37 | $21.64 | x |
| 1998-12-31 | $1.48 | $21.64 | x |
| 1999-12-31 | $0.70 | $21.64 | x |
| 2000-12-31 | $0.71 | $21.64 | x |
| 2001-12-31 | $0.46 | $21.64 | x |
| 2002-12-31 | $0.74 | $21.64 | x |
| 2003-12-31 | $5.18 | $21.64 | x |
| 2004-12-31 | $4.96 | $21.64 | x |
| 2005-12-31 | $3.77 | $21.64 | x |
| 2006-12-31 | $3.07 | $21.64 | x |
| 2007-12-31 | $2.27 | $21.64 | x |
| 2008-12-31 | $2.02 | $21.64 | x |
| 2009-12-31 | $1.85 | $21.64 | x |
| 2010-12-31 | $1.49 | $21.64 | x |
| 2011-12-31 | $1.21 | $21.64 | x |
| 2012-12-31 | $1.22 | $21.64 | x |
| 2013-12-31 | $-0.37 | $21.64 | x |
| 2014-12-31 | $0.69 | $21.64 | x |
| 2015-12-31 | $1.56 | $21.64 | x |
| 2016-12-31 | $1.02 | $21.64 | x |
| 2017-12-31 | $2.02 | $21.64 | x |
| 2018-12-31 | $0.07 | $21.64 | x |
| 2019-12-31 | $-0.78 | $21.64 | x |
| 2020-12-31 | $2.95 | $21.64 | x |
| 2021-12-31 | $1.34 | $21.64 | x |
| 2022-12-31 | $-0.35 | $21.64 | x |
| 2023-12-31 | $1.09 | $21.64 | x |
| 2024-12-31 | $0.78 | $21.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avadel Pharmaceuticals PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.87%
- • Asset Turnover: 1.03x
- • Equity Multiplier: 2.22x
- Recent ROE (-66.13%) is above the historical average (-159.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -29.87% | -140.82% | 0.16x | 1.29x | $-9.21 Million |
| 1997 | -47.55% | -83.95% | 0.38x | 1.50x | $-8.23 Million |
| 1998 | -43.92% | -82.04% | 0.38x | 1.42x | $-9.59 Million |
| 1999 | -73.83% | -60.63% | 0.74x | 1.65x | $-7.60 Million |
| 2000 | -86.94% | -86.78% | 0.54x | 1.87x | $-10.55 Million |
| 2001 | -38.27% | -21.96% | 0.72x | 2.42x | $-3.62 Million |
| 2002 | 24.46% | 16.33% | 0.80x | 1.88x | $1.78 Million |
| 2003 | -3.80% | -13.88% | 0.20x | 1.38x | $-12.70 Million |
| 2004 | 10.71% | 22.56% | 0.38x | 1.25x | $823.30K |
| 2005 | -31.59% | -116.01% | 0.19x | 1.44x | $-36.04 Million |
| 2006 | -48.20% | -152.91% | 0.20x | 1.57x | $-42.50 Million |
| 2007 | -69.08% | -102.95% | 0.36x | 1.86x | $-43.20 Million |
| 2008 | -24.89% | -31.29% | 0.42x | 1.89x | $-16.94 Million |
| 2009 | -25.50% | -27.16% | 0.45x | 2.10x | $-15.93 Million |
| 2010 | -24.72% | -24.20% | 0.50x | 2.06x | $-12.61 Million |
| 2011 | -29.45% | -26.91% | 0.47x | 2.33x | $-11.75 Million |
| 2012 | -10.58% | -12.37% | 0.22x | 3.85x | $-6.28 Million |
| 2013 | 0.00% | -191.26% | 0.19x | 0.00x | $-41.97 Million |
| 2014 | -341.06% | -574.66% | 0.08x | 7.00x | $-87.40 Million |
| 2015 | 59.91% | 23.47% | 0.81x | 3.17x | $33.87 Million |
| 2016 | -98.12% | -27.47% | 0.61x | 5.84x | $-45.48 Million |
| 2017 | 79.53% | 38.93% | 0.69x | 2.98x | $58.80 Million |
| 2018 | -3428.20% | -92.29% | 0.54x | 68.45x | $-95.58 Million |
| 2019 | 0.00% | -56.11% | 0.39x | 0.00x | $-30.31 Million |
| 2020 | 4.33% | 31.47% | 0.07x | 1.92x | $-9.20 Million |
| 2021 | -98.83% | 0.00% | 0.00x | 3.16x | $-85.15 Million |
| 2022 | 0.00% | -9188.77% | 0.01x | 0.00x | $-135.35 Million |
| 2023 | -182.67% | -573.17% | 0.17x | 1.88x | $-169.05 Million |
| 2024 | -66.13% | -28.87% | 1.03x | 2.22x | $-56.22 Million |
Industry Comparison
This section compares Avadel Pharmaceuticals PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avadel Pharmaceuticals PLC (AVDL) | $98.22 Million | -29.87% | 1.03x | $1.98 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |